Projects per year
Fingerprint
Dive into the research topics where Catherine Welsh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 1 Finished
Research output
-
A Breast Cancer Review: Through the Eyes of the Doctor, Nurse, and Patient
Klevos, G., Ezuddin, N. S., Vinyard, A., Ghaddar, T., Gort, T., Almuna, A., Abisch, A. & Welsh, C., Sep 1 2017, In: Journal of Radiology Nursing. 36, 3, p. 158-165 8 p.Research output: Contribution to journal › Review article › peer-review
6 Scopus citations -
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., Slingerland, J., Silva, O., Welsh, C., Schuhwerk, K., Seo, P., Pegram, M. D. & Glück, S., Feb 2012, In: Breast cancer research and treatment. 132, 1, p. 215-223 9 p.Research output: Contribution to journal › Article › peer-review
56 Scopus citations -
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Lobo, C., Lopes, G., Baez, O., Castrellon, A., Ferrell, A., Higgins, C., Hurley, E., Hurley, J., Reis, I., Richman, S., Seo, P., Silva, O., Slingerland, J., Tukia, K., Welsh, C. & Glück, S., Sep 2010, In: Breast cancer research and treatment. 123, 2, p. 427-435 9 p.Research output: Contribution to journal › Article › peer-review
58 Scopus citations -
Erratum: Timing of cyclin D1 expression within G1 phase is controlled by Rho (Nature Cell Biology (2001) 3 (950-957))
Welsh, C. F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A. & Assoian, R. K., Dec 2009, In: Nature Cell Biology. 11, 12, p. 1496 1 p.Research output: Contribution to journal › Comment/debate › peer-review
-
A phase II trial of split, low-dose docetaxel and low-dose capecitabine: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer
Silva, O., Lopes, G., Morgenzstern, D., Lobo, C., Doliny, P., Santos, E., Abdullah, S., Gautam, U., Reis, I., Welsh, C., Slingerland, J., Hurley, J. & Gluck, S., Apr 2008, In: Clinical breast cancer. 8, 2, p. 162-167 6 p.Research output: Contribution to journal › Article › peer-review
11 Scopus citations